Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study MG Kaya, M Ozkan, O Gunebakmaz, H Akkaya, EG Kaya, M Akpek, ... International journal of cardiology 167 (5), 2306-2310, 2013 | 358 | 2013 |
Protective effects of spironolactone against anthracycline‐induced cardiomyopathy M Akpek, I Ozdogru, O Sahin, M Inanc, A Dogan, C Yazici, V Berk, ... European journal of heart failure 17 (1), 81-89, 2015 | 240 | 2015 |
Outcome of non-metastatic male breast cancer: 118 patients ÜY Arslan, B Öksüzoğlu, N Özdemir, S Aksoy, N Alkış, A Gök, MA Kaplan, ... Medical Oncology 29, 554-560, 2012 | 87 | 2012 |
Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer M Inanc, M Ozkan, H Karaca, V Berk, O Bozkurt, AO Duran, E Ozaslan, ... Medical oncology 31, 1-8, 2014 | 71 | 2014 |
Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients AO Duran, M Inanc, H Karaca, I Dogan, V Berk, O Bozkurt, E Ozaslan, ... Asian Pacific Journal of Cancer Prevention 15 (15), 6449-6453, 2014 | 69 | 2014 |
Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? B Cetin, V Berk, MA Kaplan, B Afsar, G Tufan, M Ozkan, A Isikdogan, ... Clinical genitourinary cancer 11 (2), 141-148, 2013 | 52 | 2013 |
Factors affecting prognosis in metastatic colorectal cancer patients B Eker, E Ozaslan, H Karaca, V Berk, O Bozkurt, M Inanc, AO Duran, ... Asian Pacific Journal of Cancer Prevention 16 (7), 3015-3021, 2015 | 41 | 2015 |
Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients O Bozkurt, H Karaca, V Berk, M Inanc, AO Duran, E Ozaslan, M Ucar, ... JBUON 12, 14, 2015 | 40 | 2015 |
Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients H Demiraslan, M Sevim, Ç Pala, S Durmaz, V Berk, L Kaynar, G Metan International journal of hematology 97, 414-420, 2013 | 39 | 2013 |
Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients H Demiraslan, M Sevim, Ç Pala, S Durmaz, V Berk, L Kaynar, G Metan International journal of hematology 97, 414-420, 2013 | 39 | 2013 |
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology V Berk, MA Kaplan, O Tonyali, S Buyukberber, O Balakan, M Ozkan, ... Asian Pacific Journal of Cancer Prevention 14 (12), 7367-7369, 2013 | 38 | 2013 |
Treatment regimen with bevacizumab decreases mean platelet volume in patients with metastatic colon cancer H Mutlu, V Berk, H Karaca, A Erden, T Aslan, Z Akca Clinical and Applied Thrombosis/Hemostasis 18 (5), 546-548, 2012 | 38 | 2012 |
Prevalence of Encephalitozoon intestinalis and Enterocytozoon bieneusi in cancer patients under chemotherapy B Hamamcı, Ü Çetinkaya, V Berk, L Kaynar, S Kuk Mikrobiyoloji bulteni 49 (1), 105-113, 2015 | 37 | 2015 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents B Cetin, M Kaplan, V Berk, S Ozturk, M Benekli, A Isikdogan, M ÖZKAN, ... Asian Pacific Journal of Cancer Prevention 13 (3), 2012 | 37 | 2012 |
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience M ÖZKAN, V Berk, M Kaplan, M Benekli, U Coskun, A Bilici, M Gumus, ... Neoplasma 59 (1), 2012 | 36 | 2012 |
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO) B Cetin, M Benekli, I Turker, L Koral, A Ulas, F Dane, B Oksuzoglu, ... Journal of chemotherapy 26 (5), 300-305, 2014 | 35 | 2014 |
XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer V Berk, N Ozdemir, M Ozkan, S Aksoy, N Turan, A Inal, O Balakan, ... Hepatogastroenterology 59 (120), 2635-9, 2012 | 32 | 2012 |
D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer M Inanc, O Er, H Karaca, V Berk, M Ozkan, M Dikilitas, F Elmali J buon 18 (2), 391-397, 2013 | 31 | 2013 |
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer N Turan, M Benekli, D Koca, BO Ustaalioglu, F Dane, N Ozdemir, A Ulas, ... Oncology 84 (1), 14-21, 2012 | 30 | 2012 |
Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer M Ozkan, IH Akbudak, K Deniz, M Dikilitas, GG Dogu, V Berk, H Karaca, ... Asian Pac J Cancer Prev 11 (1), 181-185, 2010 | 28 | 2010 |